Inclusion Criteria:

          1. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

          2. Known FGFR aberration status and tumor type that meet all of the criteria for 1 of the
             following cohorts:

             a. Cohort A

             i. Histologically-confirmed, locally-advanced, advanced, or metastatic solid tumors
             harboring a FGFR1-4

        ii. Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) Version
        1.1

        iii. Had disease progression/recurrence after standard treatment for their cancer

        b. Cohort B

        i. Histologically-confirmed, locally-advanced, advanced, or metastatic gastric or
        gastroesophageal junction cancer harboring a FGFR2 amplification.

        ii. Measurable disease per RECIST 1.1

        iii. Received at least 2 prior systemic regimens for advanced/metastatic disease

        iv. Experienced disease progression/recurrence during or after the most recent prior
        systemic treatment for advanced/metastatic gastric cancer or GEJ cancer

        c. Cohort C

        i. Confirmed myeloid or lymphoid neoplasms as defined by WHO criteria with a FGFR1
        rearrangement

        ii. Not a candidate for hematological stem cell transplant (HSCT) or relapsed after HSCT
        and donor lymphocyte infusion, and progressed and not a candidate for other therapies

        Exclusion Criteria:

          1. History and/or current evidence of any of the following disorders:

               1. Non-tumor related alteration of the calcium-phosphorus homeostasis that is
                  considered clinically significant in the opinion of the Investigator

               2. Ectopic mineralization/calcification including, but not limited to, soft tissue,
                  kidneys, intestine, or myocardia and lung, considered clinically significant in
                  the opinion of the Investigator

               3. Retinal or corneal disorder confirmed by retinal/corneal examination and
                  considered clinically significant in the opinion of the Investigator.

          2. Prior treatment with an FGFR inhibitor

          3. Brain metastases that are untreated or clinically or radiologically unstable (that is,
             have been stable for <1 month)